Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
YppJHmuhScqcAkXf
